Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-specific cytotoxic T lymphocyte therapy in high-risk AML and MDS
KCT0002515Phase 2Completed
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Apr 2007
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of WT1-CTL in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Seoul St. Mary's Hospital. Primary endpoints: Safety of WT1-specific CTL therapy and Disease recurrence. Started Apr 2007; status: completed.
02
Drugs
WT1-CTL
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on KCT0002515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002515.